



October 7, 2020

MedicaMetric Completes Conversion to Corporation

MedicaMetric's conversion to a C-Corp positions the company for long-term value creation for its shareholders

BOSTON, MASSACHUSETTS (October 7, 2020) – MedicaMetric announced today that it has completed its planned conversion to a Delaware corporation from a limited liability company. Existing shareholders will receive a final Schedule K-1 in March 2021. Following today's conversion, any future distributions will generally be dividends for U.S. tax purposes and shareholders will receive a Form 1099-DIV.

"We are pleased to have completed our conversion to a corporation," said MedicaMetric's Co-Founders Satish Vankayalapati and Robert Rudelius. We believe our structure and approach, which is transparent in governance and aligned with our investors, sets the stage for MedicaMetric to drive sustainable value for our shareholders over the long-term."

About MedicaMetric

MedicaMetric develops innovative technologies and device solutions that transform the healthcare status quo, leading to better medical outcomes, streamlined care and enhanced patient experience.

We are leading the development of a new paradigm that transforms the diagnosis, treatment, and management of prostate health by filling the gap between PSA testing and imaging / biopsies. The ProstaMetric system is a minimally invasive medical device designed to accurately measure the volume of the prostate gland early in the diagnostic process. ProstaMetric helps physicians assess a patient's prostate status to better plan and monitor diagnostic procedures, treatments, drug therapies, and guide recommendations for active surveillance versus prostate biopsies.

MedicaMetric is planning on releasing a number of devices including our SureSet™ Securement device, which secures the catheter hub and infusion tube with a single site bandage and organizes the tubing for easy access and removal. This one simple

device streamlines infusion set-up, allows safe and easy access, while reducing variation and improve safety.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

MedicaMetrix, Inc.

InvestorRelations@medicametrix.com



Source: MedicaMetrix, Inc.

Released October 7, 2020